Pathologic Ultrastaging Improves Micrometastasis Detection in Sentinel Lymph Nodes During Endometrial Cancer Staging
- 1 June 2013
- journal article
- Published by BMJ in International Journal of Gynecologic Cancer
- Vol. 23 (5), 964-970
- https://doi.org/10.1097/igc.0b013e3182954da8
Abstract
ObjectiveTo describe the incidence of low-volume ultrastage-detected metastases in sentinel lymph nodes (SLNs) identified at surgical staging for endometrial carcinoma and to correlate it with depth of myoinvasion and tumor grade.MethodsWe reviewed all patients who underwent primary surgery for endometrial carcinoma with successful mapping of at least one SLN at our institution from September 2005 to December 2011. All patients underwent a cervical injection for mapping. The SLN ultrastaging protocol involved cutting an additional 2 adjacent 5-μm sections at each of 2 levels, 50-μm apart, from each paraffin block lacking metastatic carcinoma on routine hematoxylin and eosin (H&E) staining. At each level, one slide was stained with H&E and with immunohistochemistry (IHC) using anticytokeratin AE1:AE3.Micrometastases (tumor deposits >0.2 mm and ≤2 mm) and isolated tumor cells (≤0.2 mm) were classified as low-volume ultrastage-detected metastases if pathologic ultrastaging was the only method allowing detection of such nodal disease.ResultsOf 508 patients with successful mapping, 413 patients (81.3%) had endometrioid carcinoma. Sixty-four (12.6%) of the 508 patients had positive nodes: routine H&E detected 35 patients (6.9%), ultrastaging detected an additional 23 patients (4.5%) who would have otherwise been missed (4 micrometastases and 19 isolated tumor cells), and 6 patients (1.2%) had metastatic disease in their non-SLNs. The incidence rates of low-volume ultrastage-detected nodal metastases in patients with grades 1, 2, and 3 tumors were 3.8%, 3.4%, and 6.9%, respectively. The frequency rates of low-volume ultrastage-detected metastases in patients with a depth of myoinvasion of 0, less than 50%, and 50% or more were 0.8%, 8.0%, and 7.4%, respectively. Lymphovascular invasion was present in 20 (87%) of the cases containing low-volume ultrastage-detected metastases in the lymph nodes.ConclusionsSentinel lymph node mapping with pathologic ultrastaging in endometrial carcinoma detects additional low-volume metastases (4.5%) that would otherwise go undetected with routine evaluations. Our data support the incorporation of pathologic ultrastaging of SLNs in endometrial carcinoma with any degree of myoinvasion. The oncologic significance of low-volume nodal metastases requires long-term follow-up.Keywords
This publication has 15 references indexed in Scilit:
- The importance of applying a sentinel lymph node mapping algorithm in endometrial cancer staging: Beyond removal of blue nodesGynecologic Oncology, 2012
- Sentinel lymph node biopsy in endometrial cancer: Meta-analysis of 26 studiesGynecologic Oncology, 2011
- Cytokeratin‐positive cells in sentinel lymph nodes in breast cancer are not random eventsCancer, 2004
- Immunohistochemically detected tumor cells in the sentinel lymph nodes of patients with breast carcinomaCancer, 2004
- Cytokeratin staining of resected lymph nodes may improve the sensitivity of surgical staging for endometrial cancer☆Gynecologic Oncology, 2003
- Recommendations for Sentinel Lymph Node Processing in Breast CancerThe American Journal of Surgical Pathology, 2002
- Occult Lymph Node Metastases Detected by Cytokeratin Immunohistochemistry Predict Recurrence in Node-Negative Endometrial CancerGynecologic Oncology, 2001
- Detection of Micrometastasis by Cytokeratin-20 (Reverse Transcription Polymerase Chain Reaction) in Lymph Nodes of Patients with Endometrial CancerGynecologic Oncology, 2000
- Benign Transport of Breast Epithelium Into Axillary Lymph Nodes After BiopsyAmerican Journal of Clinical Pathology, 2000
- Surgical pathologic spread patterns of endometrial cancer: A gynecologic oncology group studyCancer, 1987